Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 7/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6700963 | 0.79 | PTPN11 (0.47) | PTPN11 | |
| SCHEMBL20064101 | 0.79 | ALDH1A1 (0.48) | CYP3A4CYP2D6TSHRMEN1KMT2A | |
| SCHEMBL647719 | 0.78 | HSD17B10 (0.58) | CYP3A4CYP2D6TSHRMEN1KMT2A | |
| SCHEMBL7391400 | 0.78 | PTPN11 (0.53) | PTPN11 | |
| SCHEMBL5362054 | 0.76 | CYP3A4 (0.49) | CYP3A4CYP2D6TSHRMEN1KMT2A | |
| SCHEMBL648827 | 0.76 | ADRB1 (0.62) | KMT2AALDH1A1KDM4EPTPN11 | |
| SCHEMBL22031729 | 0.75 | PTPN11 (0.41) | PTPN11 | |
| SCHEMBL30079990 | 0.75 | CYP3A4 (0.56) | CYP3A4CYP2D6TSHRMEN1KMT2A | |
| SCHEMBL10498542 | 0.75 | LMNA (0.70) | CYP3A4CYP2D6TSHRMEN1KMT2A | |
| SCHEMBL6663539 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7666869-B2 | to provide an aliphatic nitrogen-containing 5-membered ring compound represented by the formula [I]:** Image-1wherein symbols in the formula have the following meanings;A: CH2 or S , antidiabetic agents | MITSUBISHI TANABE PHARMA CORP. (JP) | 2010-02-23 | — | — | US | disclosed |
| EP-1323710-B1 | NITROGENOUS FIVE-MEMBERED RING COMPOUNDS | MITSUBISHI TANABE PHARMA CORP (JP) | 2008-09-10 | — | — | EP | disclosed |
| US-20080153821-A1 | Nitrogen-containing 5-membered ring compound | TANABE SEIYAKU CO., LTD. | 2008-06-26 | — | — | US | disclosed |
| US-7332487-B2 | Nitrogen-containing 5-membered ring compound | TANABE SEIYAKU CO., LTD. (JP) | 2008-02-19 | — | — | US | disclosed |
| CN-1891689-A | Aliphatic nitrogen - containing 5 - membered ring compound | TANABE SEIYAKU CO (JP) | 2007-01-10 | — | — | CN | disclosed |
| US-7138397-B2 | Nitrogenous 5-membered ring compounds | TANABE SEIYAKU CO., LTD. (JP) | 2006-11-21 | — | — | US | disclosed |
| US-20060241146-A1 | Nitrogen-containing 5-membered ring compound | TANABE SEIYAKU CO., LTD. | 2006-10-26 | — | — | US | disclosed |
| CN-1257891-C | Nitrogenous five-membered ring compound | TANABE SEIYAKU CO (JP) | 2006-05-31 | — | — | CN | disclosed |
| US-20050054678-A1 | Nitrogenous five-membered ring compounds | TANABE SEIYAKU CO., LTD. (JP) | 2005-03-10 | — | — | US | disclosed |
| US-20040180925-A1 | Dipeptidylpeptidase-IV inhibitor | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-09-16 | — | — | US | disclosed |
| CN-1468216-A | Nitrogenous five-membered ring compound | ������ҩ��ʽ���� | 2004-01-14 | — | — | CN | disclosed |
| EP-1354882-A1 | DIPEPTIDYL PEPTIDASE IV INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2003-10-22 | — | — | EP | disclosed |
| EP-1323710-A1 | NITROGENOUS FIVE-MEMBERED RING COMPOUNDS | Tanabe Seiyaku Co., Ltd. (JP) | 2003-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241146-A1 | Nitrogen-containing 5-membered ring compound | ALK, SCO2, NPR1 | CYP3A4 705/4885CYP2D6 845/4885TSHR 2779/4885 |
| US-20050054678-A1 | Nitrogenous five-membered ring compounds | ALK, NPR1, SCO2 | CYP3A4 707/4885CYP2D6 816/4885TSHR 2647/4885 |
| US-20040180925-A1 | Dipeptidylpeptidase-IV inhibitor | DPP4, DPP3, DPP9 | CYP3A4 972/4885CYP2D6 960/4885TSHR 2126/4885 |
| US-20080153821-A1 | Nitrogen-containing 5-membered ring compound | ALK, SCO2, NPR1 | CYP3A4 722/4885CYP2D6 931/4885TSHR 2651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.